Distinguished in Alport Syndrome

Dr. Anjay Rastogi

Nephrology
The Regents Of The University Of California
200 Medical Plaza, 
Los Angeles, CA 
Offers Telehealth
Distinguished in Alport Syndrome
The Regents Of The University Of California
200 Medical Plaza, 
Los Angeles, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Anjay Rastogi is a Nephrologist in Los Angeles, California. Dr. Rastogi is rated as a Distinguished provider by MediFind in the treatment of Alport Syndrome. His top areas of expertise are Autosomal Dominant Polycystic Kidney Disease, Polycystic Kidney Disease, High Potassium Level, Chronic Kidney Disease, and Kidney Transplant.

His clinical research consists of co-authoring 95 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 2 clinical trials in the study of Alport Syndrome.

Specialties
Nephrology
Licenses
Internal Medicine in CA
Hospital Affiliations
Ronald Reagan UCLA Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
200 Medical Plaza, Los Angeles, CA 90095
Other Locations
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
2020 Santa Monica Blvd, Suite 210, Santa Monica, CA 90404
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
900 Weyburn Place, Suite 14 171, Los Angeles, CA 90095

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome
A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome
Enrollment Status: Completed
Publish Date: June 11, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Autosomal Dominant Polycystic Kidney Disease
A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Autosomal Dominant Polycystic Kidney Disease
Enrollment Status: Terminated
Publish Date: June 03, 2025
Intervention Type: Drug
Study Drug: Bardoxolone
Study Phase: Phase 3
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases
Enrollment Status: Completed
Publish Date: June 03, 2025
Intervention Type: Drug
Study Phase: Phase 2
An Extended Access Program to Assess Long Term Safety of Bardoxolone Methyl in Patients With Chronic Kidney Disease
An Extended Access Program to Assess Long Term Safety of Bardoxolone Methyl in Patients With Chronic Kidney Disease
Enrollment Status: Terminated
Publish Date: June 03, 2025
Intervention Type: Drug
Study Drug: Bardoxolone
Study Phase: Phase 3
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2024
Intervention Type: Biological
Study Drug: 4D-310
Study Phase: Phase 1/Phase 2
A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Darbepoetin Alfa
A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Darbepoetin Alfa
Enrollment Status: Completed
Publish Date: April 02, 2024
Intervention Type: Drug
Study Drugs: Daprodustat, Darbepoetin Alpha
Study Phase: Phase 3
A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta
A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Biological
Study Drugs: PRX-102 (Pegunigalsidase Alfa), Agalsidase Beta
Study Phase: Phase 3
An Open-Label Study of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease Who Previously Experienced Abnormal Liver Chemistry Test Results While Receiving Tolvaptan: The ALERT Study
An Open-Label Study of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease Who Previously Experienced Abnormal Liver Chemistry Test Results While Receiving Tolvaptan: The ALERT Study
Enrollment Status: Terminated
Publish Date: April 10, 2023
Intervention Type: Drug
Study Drug: Lixivaptan
Study Phase: Phase 3
A Double-blind Randomized Parallel Group Study of the Efficacy and Safety of Tesevatinib in Subjects With Autosomal Dominant Polycystic Kidney Disease
A Double-blind Randomized Parallel Group Study of the Efficacy and Safety of Tesevatinib in Subjects With Autosomal Dominant Polycystic Kidney Disease
Enrollment Status: Completed
Publish Date: February 06, 2023
Intervention Type: Drug
Study Drug: Tesevatinib
Study Phase: Phase 2
A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 (Tesevatinib) in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 (Tesevatinib) in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Enrollment Status: Completed
Publish Date: November 08, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

95 Total Publications

Cardiovascular Complications in ADPKD.
Cardiovascular Complications in ADPKD.
Journal: Kidney international reports
Published: May 01, 2025
Similar Doctors
Advanced in Alport Syndrome
Dr. Ali Hariri
Nephrology
Advanced in Alport Syndrome
Dr. Ali Hariri
Nephrology
5901 W Olympic Blvd, 305, 
Los Angeles, CA 
 (5.0 miles away)
323-655-5068
Languages Spoken:
English
See accepted insurances

Ali Hariri is a Nephrologist in Los Angeles, California. Dr. Hariri is rated as an Advanced provider by MediFind in the treatment of Alport Syndrome. His top areas of expertise are Alport Syndrome, Autosomal Dominant Polycystic Kidney Disease, Polycystic Kidney Disease, and Chronic Kidney Disease.

Advanced in Alport Syndrome
Dr. Mohamed A. El-Shahawy
Nephrology
Advanced in Alport Syndrome
Dr. Mohamed A. El-Shahawy
Nephrology

Academic Medical Research Institute Inc

5830 Whittier Blvd, 
Los Angeles, CA 
 (17.6 miles away)
323-725-0051
Languages Spoken:
English
See accepted insurances

Mohamed El-Shahawy is a Nephrologist in Los Angeles, California. Dr. El-Shahawy is rated as a Distinguished provider by MediFind in the treatment of Alport Syndrome. His top areas of expertise are High Potassium Level, End-Stage Renal Disease (ESRD), Gallbladder Disease, Islet Cell Transplantation, and Gastrostomy.

Advanced in Alport Syndrome
Dr. Carl M. Grushkin
Pediatric Nephrology | Nephrology
Advanced in Alport Syndrome
Dr. Carl M. Grushkin
Pediatric Nephrology | Nephrology

Childrens Hospital Los Angeles Medical Group Inc

4650 W Sunset Blvd, 
Los Angeles, CA 
 (9.2 miles away)
323-361-8408
Languages Spoken:
English
See accepted insurances

Carl Grushkin is a Pediatric Nephrologist and a Nephrologist in Los Angeles, California. Dr. Grushkin is rated as an Advanced provider by MediFind in the treatment of Alport Syndrome. His top areas of expertise are Horseshoe Kidney, Alport Syndrome, Renal Coloboma Syndrome, and Henoch-Schonlein Purpura.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rastogi's expertise for a condition
ConditionClose
View All 34 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile